Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 242
Tipo Título / Nombre Autor(es) Año
Correction to: Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus Montesinos P, Bergua J, Infante J, Esteve J, Guimaraes JE, Sierra J, Sanz MÁ 2020
A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLREo8 PETHEMA trial Ribera JM, Morgades M, Montesinos P, Tormo M..., Bergua J, PETHEMA Group Spanish Society of Hematology 2020
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols Sobas M, Rodriguez-Veiga R, Vellenga E, Paluszewska M, De la Serna J..., Bergua J 2020
Relación entre transfusión materna previa y enfermedad hemolítica del recién nacido mediada por anti-c y autoanticuerpo anti-d Moriano Palacios B, Ibáñez Espacio F, Cáceres Hernández S, Rodríguez López A, Arcos Carmona MJ, Súarez Varela Pineda S, Cardesa Cabrera R, Bermejo Vega N, Casas Avilés I, Ferre Bermejo O, Espina García M, Bañas Llanos H, Cabrera Silva C, Carnicero González F, Bergua Burgués JM 2019
Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients Ribera JM, García O, Cervera M, Rguez C, Sirvent M, Vall-Llovera F, Abrisqueta P, Serrano J, Buendia B, Montesinos Fernández P, Vives S, Bergua Burgues JM, Bastos-Oreiro MB, Acuña E, Moreno MJ [et.al] 2019
ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma Vitolo U, Witzig TE, Gascoyne RD, Scott DW, Zhang QZ, Jurczak W, Ózcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Plazza F, Mócikova H, Molinari AL, Yoon DH, Cavallo F, Tani M, Izutsu K, Kato K, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Chlappella A, Nowakowski GS on behalf of the&10, ROBUST study investigators 2019
Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial Ayal RM, Rapado I, Martínez-Cuadron D, Onecha E, Rufian L, Juarez A, Bergua Burgues JM, Vives S, Algarra JL, Torno M, Martínez P, Serrano J, Herrera P, Salamero O, Lavilla E, Gil C, López Lorenzo JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, l Pavia B, Barragán E, Prosper F, Sanz MA, Martínez López J, Montesinos Fernández P 2019
Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies Bogliolo M, Pujol R, Aza-Carmona M, Muñoz-Subirana N, Rodríguez-Santiago B, Casado JA, Rio P, Bauser C, Reina-Castillón J, López-Sánchez M, González-Quereda L, Gallano P, Catalá A, Ruiz-Llobet A, Badell I, Díaz-Heredia C, Hladun R, Senent L, Argiles B, Bergua Burgues JM, Bañez F, Arrizabalaga B, López Almaraz R, Lopez M, Figuera Á, Molinés A, Pérez de Soto I, Hernando I, Muñoz JA, Del Rosario Marin M, Balmaña J, Stjepanovic N, Carrasco E, Cuesta I, Cosuelo JM, Regueiro A, Moraleda Jimenez J, Galera-Miñarro AM, Rosiñol L, Carrió A, Beléndez-Bieler C, Escudero Soto A, Cela E, de la Mata G, Fernández-Delgado R, Garcia-Pardos MC, Sáez-Villaverde R, Barragaño M, Portugal R, Lendinez F, Hernadez I, Vagace JM, Tapia M, Nieto J, Garcia M, Gonzalez M, Vicho C, Galvez E, Valiente A, Antelo ML, Ancliff P, Garcia F, Dopazo J, Sevilla J, Paprotka T, Pérez-Jurado LA, Bueren J, Surralles J. 2019
Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study Chiappella A, Witzig E, Cocks K, Greenwood M, Williams A, Scott DW, Gascoyne RD, Yamamoto K, Jurczak W, Özcan M, Belada D, Bergua Burgues JM, Piazza F, Visco C, Musuraca G, Margunato Debay S, Czuczman M, Zhai M, Braverman J, Vitolo U, Nowakowski G 2019
Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry Bergua Burgues JM, Cano-Ferri I, Martínez Cuadron D, Boluda B, Martínez Sánchez P, Rodríguez Veiga R, Esteve J, Vives S, Serrano J, Vidriales MB, Salamero O, Carretero C, Jiménez Ubieto A, Casas I, Cardesa R, Díaz Beyá M, Brunet S, benavente C, Pérez Simón JA, Moscardo F, Aguilar E, Pérez Encinas M, López Martínez A, Rodríguez C, Cabello A, Labrador J, Costilla L, Sossa C, Bernal del Castillo T, Sanz MA, Montesinos P 2019